Related Experiment Video
Updated: Apr 30, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Continuation vs Switching Direct Oral Anticoagulant Therapy After Breakthrough Stroke
Lucio D'Anna1,2, Francesca Gabriele3, Raffaele Ornello3
1Department of Stroke and Neuroscience, Charing Cross Hospital, Imperial College London NHS (National Health Service) Healthcare Trust, London, United Kingdom.
Insights
Switching direct oral anticoagulants (DOACs) after a stroke in atrial fibrillation (AF) patients offers no short-term benefit over continuing the same DOAC. This study suggests current strategies may not improve outcomes for these high-risk patients.
Area of Science:
- Cardiology and Neurology
- Pharmacological Interventions
- Clinical Trial Design
Background:
- Management of ischemic stroke in atrial fibrillation (AF) patients on direct oral anticoagulants (DOACs) is inconsistent.
- Switching anticoagulation is common practice, but lacks robust supporting evidence.
- Understanding optimal anticoagulation strategies post-stroke is crucial for secondary prevention.
Purpose of the Study:
- To determine if continuing the same DOAC is noninferior to switching anticoagulant therapy for 90-day clinical outcomes.
- To evaluate the net clinical benefit of switching versus continuation strategies in AF patients post-ischemic stroke.
Main Methods:
- A multicenter, registry-based cohort study with an emulated target trial design.
- Included 1006 adult AF patients experiencing ischemic stroke despite uninterrupted DOAC therapy.
- Used inverse probability of treatment weighting (IPTW) to adjust for baseline confounding.
- Primary outcome: 90-day net clinical benefit (recurrent ischemic stroke and moderate-to-severe bleeding).
Main Results:
- The 90-day net clinical benefit was similar between switching (4.9%) and continuation (5.1%) groups (risk difference: -0.3 percentage points).
- The study met its noninferiority criterion for net clinical benefit.
- Secondary outcomes for recurrent ischemic events and bleeding also fell within noninferiority margins.
- Noninferiority was not demonstrated for all-cause or vascular mortality.
Conclusions:
- Switching anticoagulation treatment after a breakthrough ischemic stroke in AF patients did not show a short-term benefit compared to continuing the same DOAC.
- Current findings suggest no additional benefit from switching DOACs versus continuing the prestroke DOAC.
- Further randomized clinical trials are necessary to optimize secondary prevention strategies in this patient population.
Importance:
Management after an ischemic stroke occurring despite direct oral anticoagulant (DOAC) therapy for atrial fibrillation (AF) varies widely. Switching anticoagulation is common in clinical practice, although evidence supporting this strategy is limited.
Objective:
To evaluate whether continuation of treatment with the same DOAC was noninferior to switching oral anticoagulant therapy with respect to 90-day clinical outcomes.
Design, Setting, And Participants:
This multicenter registry-based cohort study with an emulated target trial design included consecutive adult patients with AF who experienced a breakthrough ischemic stroke while receiving uninterrupted DOAC therapy and resumed anticoagulation therapy thereafter. Patients were enrolled between February 2020 and February 2025, across 35 stroke centers in 9 countries in Europe and North Africa, with a standardized 90-day follow-up. The dataset was locked on September 1, 2025. A noninferiority comparison of switching vs continuation strategies was performed. Baseline confounding was addressed using inverse probability of treatment weighting (IPTW). The primary noninferiority margin was an absolute risk difference of 3.0 percentage points in 90-day net clinical benefit.
Exposure:
The intervention group switched to treatment with a different DOAC or vitamin K antagonist; the comparator group continued therapy with the prestroke DOAC.
Main Outcomes And Measures:
The primary outcome was 90-day net clinical benefit, defined as recurrent ischemic stroke and moderate to severe bleeding. Secondary outcomes included recurrent ischemic events, symptomatic intracerebral hemorrhage, moderate to severe extracranial bleeding, all-cause mortality, and vascular death.
Results:
Among 1006 patients included in the analysis (median age, 80.4 [IQR, 73.4-85.4] years; 503 female [50.0%] and 503 [50.0%] male), 463 (46.0%) continued the same DOAC therapy and 543 (54.0%) switched therapy. After IPTW adjustment, the 90-day net clinical benefit was 4.9% with switching and 5.1% with continuation, corresponding to a risk difference of -0.3 percentage points (90% CI, -2.7 to 2.1 percentage points), meeting the prespecified noninferiority criterion. For recurrent ischemic events and bleeding outcomes, the absolute differences were within the predefined noninferiority margins. Noninferiority was not demonstrated for all-cause or vascular mortality.
Conclusions And Relevance:
In patients with breakthrough ischemic stroke during DOAC therapy, switching anticoagulation treatment was not associated with clinically meaningful short-term benefit compared with continuation. These findings suggest that switching does not provide additional benefit compared with continuing treatment with the same DOAC. Randomized clinical trials are needed to identify strategies to improve secondary prevention after a breakthrough ischemic stroke.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Hemorrhagic Stroke ll: Pathophysiology
01:17Hemorrhagic Stroke l: Introduction
01:30Continuous Renal Replacement Therapy